Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report

Jean-Marie Ledoux,1 Pascal Brun,2 Tom Chapuis,2 Paul Dumas,3 Jean Guillotin41Veterinary Surgery, Lys-Lez-Lannoy, 2AB Science, Paris, 3Laboratoire de Pathologie Vétérinaire du Nord, Ann&oelig;ullin, 4Laboratoire Départemental Public, Villeneuve d'Ascq, Fr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ledoux JM, Brun P, Chapuis T, Dumas P, Guillotin J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/08fa1fae2a234b2da044a6606b219f83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:08fa1fae2a234b2da044a6606b219f83
record_format	dspace
spelling	oai:doaj.org-article:08fa1fae2a234b2da044a6606b219f832021-12-02T08:41:37ZMedical approach to the treatment of feline injection site sarcoma with masitinib: a case report2230-2034https://doaj.org/article/08fa1fae2a234b2da044a6606b219f832014-09-01T00:00:00Zhttp://www.dovepress.com/medical-approach-to-the-treatment-of-feline-injection-site-sarcoma-wit-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034 Jean-Marie Ledoux,1 Pascal Brun,2 Tom Chapuis,2 Paul Dumas,3 Jean Guillotin41Veterinary Surgery, Lys-Lez-Lannoy, 2AB Science, Paris, 3Laboratoire de Pathologie Vétérinaire du Nord, Ann&oelig;ullin, 4Laboratoire Départemental Public, Villeneuve d'Ascq, FranceAbstract: Feline injection site sarcoma is a common tumor among cats, for which existing medical treatments do not prove to be entirely satisfactory. In this tumor, the platelet-derived growth factor receptor, a tyrosine kinase receptor, is frequently hyperactivated. In the past, clinical case reports with imatinib, a tyrosine kinase inhibitor (TKI), have demonstrated tumoral stabilization. Here we describe the use of another TKI, masitinib, which specifically inhibits c-Kit, platelet-derived growth factor receptor, and Lyn, and is currently licensed for veterinary use in canine mast cell tumors. The therapeutic results were initially satisfactory, with regression of the tumor followed by tumoral recurrence which was stabilized and moderately reduced. Further studies are suggested, in order to evaluate the relevance of TKIs in the treatment and prevention of recurrences of feline injection site sarcoma. Tumoral stabilization by means of an inexpensive and reasonably well tolerated treatment would prove to be of true therapeutic relevance, in particular for inoperable feline injection site sarcomas. Another indication for such TKIs could be in preoperative treatment as a means of facilitating surgical excision by reduction of adhesions.Keywords: fibrosarcoma, imatinib, platelet-derived growth factor receptor, tyrosine kinase receptorLedoux JMBrun PChapuis TDumas PGuillotin JDove Medical PressarticleVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol 2014, Iss default, Pp 109-113 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Veterinary medicine SF600-1100
spellingShingle	Veterinary medicine SF600-1100 Ledoux JM Brun P Chapuis T Dumas P Guillotin J Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
description	Jean-Marie Ledoux,1 Pascal Brun,2 Tom Chapuis,2 Paul Dumas,3 Jean Guillotin41Veterinary Surgery, Lys-Lez-Lannoy, 2AB Science, Paris, 3Laboratoire de Pathologie Vétérinaire du Nord, Ann&oelig;ullin, 4Laboratoire Départemental Public, Villeneuve d'Ascq, FranceAbstract: Feline injection site sarcoma is a common tumor among cats, for which existing medical treatments do not prove to be entirely satisfactory. In this tumor, the platelet-derived growth factor receptor, a tyrosine kinase receptor, is frequently hyperactivated. In the past, clinical case reports with imatinib, a tyrosine kinase inhibitor (TKI), have demonstrated tumoral stabilization. Here we describe the use of another TKI, masitinib, which specifically inhibits c-Kit, platelet-derived growth factor receptor, and Lyn, and is currently licensed for veterinary use in canine mast cell tumors. The therapeutic results were initially satisfactory, with regression of the tumor followed by tumoral recurrence which was stabilized and moderately reduced. Further studies are suggested, in order to evaluate the relevance of TKIs in the treatment and prevention of recurrences of feline injection site sarcoma. Tumoral stabilization by means of an inexpensive and reasonably well tolerated treatment would prove to be of true therapeutic relevance, in particular for inoperable feline injection site sarcomas. Another indication for such TKIs could be in preoperative treatment as a means of facilitating surgical excision by reduction of adhesions.Keywords: fibrosarcoma, imatinib, platelet-derived growth factor receptor, tyrosine kinase receptor
format	article
author	Ledoux JM Brun P Chapuis T Dumas P Guillotin J
author_facet	Ledoux JM Brun P Chapuis T Dumas P Guillotin J
author_sort	Ledoux JM
title	Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
title_short	Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
title_full	Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
title_fullStr	Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
title_full_unstemmed	Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
title_sort	medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/08fa1fae2a234b2da044a6606b219f83
work_keys_str_mv	AT ledouxjm medicalapproachtothetreatmentoffelineinjectionsitesarcomawithmasitinibacasereport AT brunp medicalapproachtothetreatmentoffelineinjectionsitesarcomawithmasitinibacasereport AT chapuist medicalapproachtothetreatmentoffelineinjectionsitesarcomawithmasitinibacasereport AT dumasp medicalapproachtothetreatmentoffelineinjectionsitesarcomawithmasitinibacasereport AT guillotinj medicalapproachtothetreatmentoffelineinjectionsitesarcomawithmasitinibacasereport
_version_	1718398404325801984

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report

Ejemplares similares